Company profile: GB Sciences
1.1 - Company Overview
Company description
- Provider of research and biotechnical development focused on plant-based therapeutics, including the PhAROS AI drug discovery platform to identify and predict active ingredients; therapies for Parkinson’s disease (animal proof-of-concept, US patent); COVID-related cytokine release syndrome therapies (positive proof-of-concept); and oral nanoparticle pain therapeutics (US patent, ongoing animal studies).
Products and services
- PhAROS Drug Discovery Platform: Research-grade AI platform used to identify plant-based active ingredients and predict their efficacy for therapeutic development
- Pain Therapeutics: Nanotechnology-based oral nanoparticles containing formulas for pain treatment, with a US patent issued and ongoing animal studies supporting continued evaluation of these orally deliverable compositions
- Parkinson’s Disease Therapies: Patent-issued therapies for Parkinson’s disease with achieved animal proof-of-concept, created to transition demonstrated in vivo activity into continued research and development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GB Sciences
CardioNexion Health
HQ: France
Website
- Description: Provider of custom medical monitoring solutions for cardiovascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CardioNexion Health company profile →
Rapidscan Pharma
HQ: United States
Website
- Description: Provider of regadenoson, a pharmacological stress agent used in the diagnosis and risk stratification of cardiovascular disease, with licensed rights to sell in Europe and select territories.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rapidscan Pharma company profile →
Miracor Medical
HQ: Belgium
Website
- Description: Provider of pressure-controlled intermittent coronary sinus occlusion (PiCSO) therapy and impulse system to treat severe heart diseases, developed and commercialized for cardiac surgeons to facilitate PiCSO treatment in myocardial infarction/heart attack patients undergoing coronary artery bypass grafting, and used during percutaneous coronary intervention (PCI) to reduce infarct size in acute myocardial infarction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Miracor Medical company profile →
CHF Solutions
HQ: United States
Website
- Description: Provider of innovative cardiac care medical devices, designing and manufacturing a device that removes excess fluid from patients with fluid overload, offering practical solutions to address unmet clinical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CHF Solutions company profile →
Carmat
HQ: France
Website
- Description: Provider of biocompatible, auto-regulated bioprosthetic total artificial hearts, including right and left ventricles designed to be as close as possible to the human heart; offers Aeson as an alternative therapeutic option for patients with advanced biventricular heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Carmat company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GB Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GB Sciences
2.2 - Growth funds investing in similar companies to GB Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GB Sciences
4.2 - Public trading comparable groups for GB Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →